MCID: LKM063
MIFTS: 53

Leukemia, Chronic Myeloid malady

Genetic diseases, Rare diseases, Blood diseases, Cancer diseases, Immune diseases categories

Aliases & Classifications for Leukemia, Chronic Myeloid

About this section
Sources:
46OMIM, 9diseasecard, 42NIH Rare Diseases, 30LifeMap Discovery®, 8Disease Ontology, 10DISEASES, 48Orphanet, 32MedlinePlus, 61UMLS, 44Novoseek, 22GTR, 33MeSH, 56SNOMED-CT, 27ICD9CM, 39NCIt, 26ICD10 via Orphanet, 62UMLS via Orphanet
See all sources

Aliases & Descriptions for Leukemia, Chronic Myeloid:

Name: Leukemia, Chronic Myeloid 46 9 42 30
Chronic Myeloid Leukemia 30 8 42 10 48 32
Chronic Granulocytic Leukemia 8 42 48
Chronic Myelogenous Leukemia 8 42 48
 
Myeloid Leukemia, Chronic 8 61
Myeloid Leukemia Chronic 44 22
Cml 8 42
Cml - Chronic Myelogenous Leukemia 8


Classifications:



Characteristics (Orphanet epidemiological data):

48
chronic myeloid leukemia:
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/100000 (France); Age of onset: Adult


External Ids:

OMIM46 608232
Disease Ontology8 DOID:8552
MeSH33 D015464
ICD9CM27 205.1
NCIt39 C3174
Orphanet48 521
ICD10 via Orphanet26 C92.1
UMLS via Orphanet62 C0023473

Summaries for Leukemia, Chronic Myeloid

About this section
MedlinePlus:32 Leukemia is cancer of the white blood cells. white blood cells help your body fight infection. your blood cells form in your bone marrow. in leukemia, the bone marrow produces abnormal white blood cells. these cells crowd out the healthy blood cells, making it hard for blood to do its work. in chronic myeloid leukemia (cml), there are too many granulocytes, a type of white blood cell. most people with cml have a gene mutation (change) called the philadelphia chromosome. sometimes cml does not cause any symptoms. if you have symptoms, they may include: fatigue weight loss night sweats fever pain or a feeling of fullness below the ribs on the left side tests that examine the blood and bone marrow diagnose cml. treatments include chemotherapy, stem cell transplants, infusion of donated white blood cells following stem cell transplants, surgery to remove the spleen, and biologic and targeted therapies. biologic therapy boosts your body's own ability to fight cancer. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

MalaCards based summary: Leukemia, Chronic Myeloid, also known as chronic myeloid leukemia, is related to chronic myelomonocytic leukemia and myelodysplastic syndrome, and has symptoms including somatic mutation, ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia. An important gene associated with Leukemia, Chronic Myeloid is BCR (breakpoint cluster region), and among its related pathways are Tyrosine Kinases / Adaptors and Gefitinib Pathway, Pharmacokinetics. The drugs busulfan and cyclophosphamide and the compounds bosutinib monohydrate and nilotinib have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related mouse phenotypes are normal and liver/biliary system.

Disease Ontology:8 A myeloid leukemia that is characterized by over production of white blood cells.

Description from OMIM:46 608232

Related Diseases for Leukemia, Chronic Myeloid

About this section

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid leukemia, chronic myeloid
Subacute Myeloid Leukemia Acute Myeloid Leukemia, Adult
Npm1-Related Acute Myeloid Leukemia Inherited Acute Myeloid Leukemia
'acute Myeloid Leukemia with T(9;11)(p22;q23)' 'acute Myeloid Leukemia with T(6;9)(p23;q34)'

Diseases related to Leukemia, Chronic Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 213)
idRelated DiseaseScoreTop Affiliating Genes
1chronic myelomonocytic leukemia31.0BCR, RUNX1
2myelodysplastic syndrome30.8ABL1, RUNX1
3myeloid leukemia30.8ABL1, RUNX1, BCR
4leukemia30.7BCR, ABL1, RUNX1
5acute leukemia30.4BCR, RUNX1, ABL1
6systemic lupus erythematosus30.3BCR, RUNX1
7gastrointestinal stromal tumor30.1BCR, ABL1
8chronic lymphocytic leukemia30.0ABL1, BCR
9retinoblastoma29.9BCR, RUNX1, ABL1
10hematopoietic stem cell transplantation10.7
11lymphoblastic leukemia10.7
12philadelphia-negative chronic myeloid leukemia10.7
13myelofibrosis10.5
14thrombocytosis10.5
15priapism10.5
16polycythemia10.5
17endotheliitis10.5
18polycythemia vera10.4
19hepatitis10.4
20subacute myeloid leukemia10.4
21sarcoma10.4
22essential thrombocythemia10.4
23glomerulonephritis10.4
24hepatitis b10.4
25polyneuropathy10.4
26obesity10.3
27neurofibromatosis, type 110.3
28bronchiolitis obliterans10.3
29bronchiolitis10.3
30bronchiolitis obliterans organizing pneumonia10.3
31acute basophilic leukemia10.3
32leukemia, juvenile myelomonocytic10.3RUNX1
33leukemoid reaction10.3
34colorectal cancer10.3
35wilms tumor10.3
36anaplastic large cell lymphoma10.3
37b-cell lymphomas10.3
38thrombocytopenia10.3
39membranoproliferative glomerulonephritis10.3
40splenic infarction10.3
41portal vein thrombosis10.3
42gynecomastia10.3
43hypercalcemia10.3
44pulmonary alveolar proteinosis10.3
45adenocarcinoma10.3
46calcinosis10.3
47colitis10.3
48colon adenocarcinoma10.3
49hypopyon10.3
50plasmacytoma10.3

Graphical network of the top 20 diseases related to Leukemia, Chronic Myeloid:



Diseases related to leukemia, chronic myeloid

Symptoms for Leukemia, Chronic Myeloid

About this section

Symptoms by clinical synopsis from OMIM:

608232

Clinical features from OMIM:

608232

HPO human phenotypes related to Leukemia, Chronic Myeloid:

id Description Frequency HPO Source Accession
1 somatic mutation HP:0001428
2 ph-positive acute lymphoblastic leukemia HP:0004848
3 chronic myelogenous leukemia HP:0005506

Drugs & Therapeutics for Leukemia, Chronic Myeloid

About this section

FDA approved drugs:

(show all 7)
id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Bosulif13 38 BOSUTINIB MONOHYDRATE Pfizer Approved September 2012
FDA Label: Bosulif
Malady that Drug Treats: Ph+ chronic myelogenous leukemia
Indications and Usage:13 BOSULIF is a kinase inhibitor indicated for the treatment of adult patients; with chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia; (CML) with resistance or intolerance to prior therapy. (1)
DrugBank Targets:11 1. Breakpoint cluster region protein; 2. Tyrosine-protein kinase ABL1; 3. Tyrosine-protein kinase Lyn; 4. Tyrosine-protein kinase HCK; 5. Proto-oncogene tyrosine-protein kinase Src; 6. Cyclin-dependent kinase 2; 7. Dual specificity mitogen-activated protein kinase kinase 1; 8. Dual specificity mitogen-activated protein kinase kinase 2; 9. Mitogen-activated protein kinase kinase kinase 2; 10. Calcium/calmodulin-dependent protein kinase type II subunit gamma
Mechanism of Action:13 
Target: tyrosine kinase/ Src-family kinases including Src, Lyn, and Hck
Action: inhibitor
FDA: Bosutinib is a tyrosine kinase inhibitor. Bosutinib inhibits the Bcr-Abl kinase that promotes CML; it is also an; inhibitor of Src-family kinases including Src, Lyn, and Hck. Bosutinib inhibited 16 of 18 imatinib-resistant forms of; Bcr-Abl expressed in murine myeloid cell lines. Bosutinib did not inhibit the T315I and V299L mutant cells. In mice,; treatment with bosutinib reduced the size of CML tumors relative to controls and inhibited growth of murine myeloid; tumors expressing several imatinib-resistant forms of Bcr-Abl.
2
Busulfex13 38 BUSULFAN Orphan Medical Approved February 1999
FDA Label: Busulfex
Malady that Drug Treats: leukemia
Indications and Usage:13 BUSULFEX is an alkylating drug indicated for:; Use in combination with cyclophosphamide as a conditioning regimen; prior to allogeneic hematopoietic progenitor cell transplantation for; chronic myelogenous leukemia (CML) (1)
DrugBank Targets:11 DNA
Mechanism of Action:13 
Target: DNA
Action: alkylyzer
FDA: Busulfan is a bifunctional alkylating agent in which two labile methanesulfonate groups are attached to opposite ends of a; four-carbon alkyl chain. In aqueous media, busulfan hydrolyzes to release the methanesulfonate groups. This produces; reactive carbonium ions that can alkylate DNA. DNA damage is thought to be responsible for much of the cytotoxicity of; busulfan.
3
Gleevec13 38 IMATINIB MESYLATE Novartis Approved May 2001
FDA Label: Gleevec
Malady that Drug Treats: chronic myeloid leukemia/Gastrointestinal stromal tumors (GISTs)
Indications and Usage:13 Gleevec"! (imatinib mesylate) is indicated for the treatment of newly diagnosed adult; patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) in chronic; phase. Follow-up is limited. ; Page 10; Gleevec is also indicated for the treatment of patients with Philadelphia chromosome; positive chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic; phase after failure of interferon-alpha therapy. Gleevec is also indicated for the treatment of; pediatric patients with Ph+ chronic phase CML whose disease has recurred after stem cell; transplant or who are resistant to interferon alpha therapy. There are no controlled trials; demonstrating a clinical benefit, such as improvement in disease-related symptoms or; increased survival.; Gleevec is also indicated for the treatment of patients with Kit (CD117) positive; unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). (See; CLINICAL STUDIES: Gastrointestinal Stromal Tumors.) The effectiveness of Gleevec in; GIST is based on objective response rate (see CLINICAL STUDIES). There are no controlled; trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or; increased survival.
DrugBank Targets:11 1. BCR/ABL fusion protein isoform X9; 2. Mast/stem cell growth factor receptor Kit; 3. RET proto-oncogene; 4. High affinity nerve growth factor receptor; 5. Macrophage colony-stimulating factor 1 receptor; 6. Platelet-derived growth factor receptor alpha; 7. Epithelial discoidin domain-containing receptor 1; 8. Tyrosine-protein kinase ABL1; 9. Platelet-derived growth factor receptor beta
Mechanism of Action:13 
Target: protein-tyrosine kinase
Action: inhibitor
FDA: Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the Bcr-Abl tyrosine; kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome; abnormality in chronic myeloid leukemia (CML). It inhibits proliferation and induces; apoptosis in Bcr-Abl positive cell lines as well as fresh leukemic cells from Philadelphia; chromosome positive chronic myeloid leukemia. In colony formation assays using ex vivo; peripheral blood and bone marrow samples, imatinib shows inhibition of Bcr-Abl positive; colonies from CML patients.; In vivo, it inhibits tumor growth of Bcr-Abl transfected murine myeloid cells as well; as Bcr-Abl positive leukemia lines derived from CML patients in blast crisis.; Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived; growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGF- and; SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces apoptosis in; gastrointestinal stromal tumor (GIST) cells, which express an activating c-kit mutation.
4
Iclusig13 38 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals Approved December 2012
FDA Label: Iclusig
Malady that Drug Treats: chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia
Indications and Usage:13 Iclusig is a kinase inhibitor indicated for the:; Treatment of adult patients with T315I-positive chronic myeloid; leukemia (chronic phase, accelerated phase, or blast phase) or T315Ipositive; Philadelphia chromosome positive acute lymphoblastic; leukemia (Ph+ ALL).; Treatment of adult patients with chronic phase, accelerated phase, or; blast phase chronic myeloid leukemia or Ph+ ALL for whom no other; tyrosine kinase inhibitor (TKI) therapy is indicated. (1); These indications are based upon response rate. There are no trials verifying an; improvement in disease-related symptoms or increased survival with Iclusig.
DrugBank Targets:11 1. Tyrosine-protein kinase ABL1; 2. Breakpoint cluster region protein; 3. Mast/stem cell growth factor receptor Kit; 4. Proto-oncogene tyrosine-protein kinase receptor Ret; 5. Angiopoietin-1 receptor; 6. Receptor-type tyrosine-protein kinase FLT3; 7. Fibroblast growth factor receptor 1; 8. Fibroblast growth factor receptor 2; 9. Fibroblast growth factor receptor 3; 10. Fibroblast growth factor receptor 4; 11. Tyrosine-protein kinase Lck; 12. Proto-oncogene tyrosine-protein kinase Src; 13. Tyrosine-protein kinase Lyn; 14. Vascular endothelial growth factor receptor 2; 15. Platelet-derived growth factor receptor alpha
Mechanism of Action:13 
Target: tyrosine kinase activity of ABL and T315I mutant ABL
Action: inhibitor
FDA: Ponatinib is a kinase inhibitor. Ponatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with; IC50 concentrations of 0.4 and 2.0 nM, respectively. Ponatinib inhibited the in vitro activity of additional kinases with IC50; concentrations between 0.1 and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC; families of kinases, and KIT, RET, TIE2, and FLT3. Ponatinib inhibited the in vitro viability of cells expressing native or; mutant BCR-ABL, including T315I. In mice, treatment with ponatinib reduced the size of tumors expressing native or; T315I mutant BCR-ABL when compared to controls.
5
Sprycel13 38 DASATINIB Bristol-Myers Squibb Approved June 2006
FDA Label: Sprycel
Malady that Drug Treats: Chronic Myeloid Leukemia
Indications and Usage:13 SPRYCEL is a kinase inhibitor indicated for the treatment of; newly diagnosed adults with Philadelphia chromosome-positive (Ph+); chronic myeloid leukemia (CML) in chronic phase. (1, 14); adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+; CML with resistance or intolerance to prior therapy including imatinib. (1,; 14); adults with Philadelphia chromosome-positive acute lymphoblastic; leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1, 14)
DrugBank Targets:11 1. Tyrosine-protein kinase ABL1; 2. Proto-oncogene tyrosine-protein kinase Src; 3. Ephrin type-A receptor 2; 4. Tyrosine-protein kinase Lck; 5. Tyrosine-protein kinase Yes; 6. Mast/stem cell growth factor receptor Kit; 7. Platelet-derived growth factor receptor beta; 8. Signal transducer and activator of transcription 5B; 9. Abelson tyrosine-protein kinase 2; 10. Tyrosine-protein kinase Fyn
Mechanism of Action:13 
Target: BCR-ABL, SRC family; (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFR² kinases
Action: inhibitor
FDA: Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family; (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFR². Based on modeling studies, dasatinib is; predicted to bind to multiple conformations of the ABL kinase.; In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate; sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia; (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the; conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCRABL; kinase domain mutations, activation of alternate signaling pathways involving the SRC; family kinases (LYN, HCK), and multi-drug resistance gene overexpression.
6
Synribo13 38 OMACETAXINE MEPESUCCINATE Teva Pharmaceutical Approved October 2012
FDA Label: Synribo
Malady that Drug Treats: chronic or accelerated phase chronic myeloid leukemia
Indications and Usage:13 SYNRIBO for Injection is indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI) (1)
DrugBank Targets:11 1. 50S ribosomal protein L2; 2. 60S ribosomal protein L3
Mechanism of Action:13 
Target: A-site cleft in the peptidyl-transferase center of the; large ribosomal subunit from a strain of archaeabacteria
Action: inhibitor of protein synthesis
FDA: The mechanism of action of omacetaxine mepesuccinate has not been fully elucidated but includes inhibition of protein synthesis and; is independent of direct Bcr-Abl binding. Omacetaxine mepesuccinate binds to the A-site cleft in the peptidyl-transferase center of the; large ribosomal subunit from a strain of archaeabacteria. In vitro, omacetaxine mepesuccinate reduced protein levels of the Bcr-Abl; oncoprotein and Mcl-1, an anti-apoptotic Bcl-2 family member. Omacetaxine mepesuccinate showed activity in mouse models of; wild-type and T315I mutated Bcr-Abl CML.
7
Tasigna13 38 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis Approved October 2007
FDA Label: Tasigna
Malady that Drug Treats: chronic myelogenous leukemia
Indications and Usage:13 Tasigna is a kinase inhibitor indicated for:; The treatment of newly diagnosed adult patients with Philadelphia; chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.; The treatment of chronic phase (CP) and accelerated phase (AP) Ph+ CML in; adult patients resistant to or intolerant to prior therapy that included imatinib.; (1.2); --------------
DrugBank Targets:11 1. Tyrosine-protein kinase ABL1; 2. Mast/stem cell growth factor receptor Kit
Mechanism of Action:13 
Target: Bcr-Abl kinase, c-kit and Platelet Derived Growth Factor (PDGF)
Action: inhibitor of signal transduction
FDA: Nilotinib is an inhibitor of the BCR-ABL kinase. Nilotinib binds to and stabilizes the inactive conformation of; the kinase domain of ABL protein. In vitro, nilotinib inhibited BCR-ABL mediated proliferation of murine; leukemic cell lines and human cell lines derived from patients with Ph+ CML. Under the conditions of the; assays, nilotinib was able to overcome imatinib resistance resulting from BCR-ABL kinase mutations, in 32 out; of 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine BCR-ABL xenograft model.; Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: BCR-ABL (20; to 60 nM), PDGFR (69 nM), c-KIT (210 nM), CSF-1R (125 to 250 nM), and DDR1 (3.7 nM).

Drug clinical trials:

Search ClinicalTrials for Leukemia, Chronic Myeloid

Search NIH Clinical Center for Leukemia, Chronic Myeloid

Inferred drug relations via UMLS61/NDF-RT40:

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Chronic Myeloid cell therapies at LifeMap Discovery.

Genetic Tests for Leukemia, Chronic Myeloid

About this section

Genetic tests related to Leukemia, Chronic Myeloid:

id Genetic test Affiliating Genes
1 Chronic Myeloid Leukemia22

Anatomical Context for Leukemia, Chronic Myeloid

About this section

MalaCards organs/tissues related to Leukemia, Chronic Myeloid:

31
Myeloid, Bone, Bone marrow, Spleen, Testes

Animal Models for Leukemia, Chronic Myeloid or affiliated genes

About this section

MGI Mouse Phenotypes related to Leukemia, Chronic Myeloid:

35
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00028738.8BCR, ABL1, RUNX1
2MP:00053708.5BCR, ABL1, RUNX1

Publications for Leukemia, Chronic Myeloid

About this section

Articles related to Leukemia, Chronic Myeloid:

idTitleAuthorsYear
1
No asthma, no parasites is a rare type of leukemia: chronic myeloid neoplasm with eosinophilia and abnormality of platelet-derived growth factor receptor alpha. (23156891)
2012

Variations for Leukemia, Chronic Myeloid

About this section

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Chronic Myeloid:

63
id Symbol AA change Variation ID SNP ID
1SETBP1p.Asp868AsnVAR_063807
2SETBP1p.Gly870SerVAR_063809
3SETBP1p.Ile871ThrVAR_063810
4SETBP1p.Glu858LysVAR_069849

Expression for genes affiliated with Leukemia, Chronic Myeloid

About this section
Search GEO for disease gene expression data for Leukemia, Chronic Myeloid.

Pathways for genes affiliated with Leukemia, Chronic Myeloid

About this section

Compounds for genes affiliated with Leukemia, Chronic Myeloid

About this section
Sources:
50PharmGKB, 11DrugBank, 44Novoseek
See all sources

Compounds related to Leukemia, Chronic Myeloid according to GeneCards Suite gene sharing:

(show all 16)
idCompoundScoreTop Affiliating Genes
1bosutinib monohydrate509.6BCR, ABL1
2nilotinib50 1110.6ABL1, BCR
3homoharringtonine44 50 1111.6BCR, ABL1
4busulfan44 50 1111.6BCR, ABL1
5ponatinib50 1110.6ABL1, BCR
6dasatinib44 50 1111.5BCR, ABL1
7cytarabine44 50 1111.4BCR, ABL1
8ceramide449.4BCR, ABL1
9phenylalanine449.3ABL1, BCR
10phosphotyrosine449.2BCR, ABL1
11imatinib44 50 1111.1BCR, ABL1, RUNX1
12dmso449.1BCR, ABL1, RUNX1
13oligonucleotide449.0RUNX1, ABL1, BCR
14threonine449.0BCR, ABL1, RUNX1
15tyrosine448.8BCR, ABL1, RUNX1
16serine448.5BCR, ABL1, RUNX1

GO Terms for genes affiliated with Leukemia, Chronic Myeloid

About this section

Biological processes related to Leukemia, Chronic Myeloid according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1platelet-derived growth factor receptor signaling pathwayGO:00480089.3BCR, ABL1
2actin cytoskeleton organizationGO:00300369.3BCR, ABL1
3regulation of cell cycleGO:00517269.2BCR, ABL1
4peptidyl-tyrosine phosphorylationGO:00181089.0BCR, ABL1

Molecular functions related to Leukemia, Chronic Myeloid according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein tyrosine kinase activityGO:00047139.2BCR, ABL1
2ATP bindingGO:00055248.5BCR, ABL1, RUNX1
3DNA bindingGO:00036778.5SETBP1, ABL1, RUNX1

Sources for Leukemia, Chronic Myeloid

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet